Zelda Therapeutics Limited, a bio-pharmaceutical company, focuses on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia.
The last earnings update was 54 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Zelda Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Zelda Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zelda Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Zelda Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Zelda Therapeutics's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Zelda Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Zelda Therapeutics is high growth as no earnings estimate data is available.
Unable to determine if Zelda Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Zelda Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Zelda Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Zelda Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Zelda Therapeutics has no long term commitments.
This treemap shows a more detailed breakdown of
Zelda Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Zelda Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Richard Miles Hopkins, Bsc (Hons), Ph.D. is Managing Director and Director at Zelda Therapeutics Ltd since July 16, 2018. Mr. Hopkins served as the Chief Executive Officer of PharmAust Limited since March 07, 2017 until May 25, 2018. Dr. Hopkins served as the Chief Executive Officer of Phylogica Limited from July 19, 2013 to October 2016 and served as its Chief Operating Officer until July 19, 2013. He served as the Chief Scientific Officer of Phylogica Limited. He was a co-founder of Phylogica and Vice President of Research. He is an experienced pharmaceutical executive with over 10 years in corporate leadership roles. His most recent research is focussed on engineering peptide leads for drug development. He has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications, several of which have been issued in the US and Europe. He carried out postdoctoral research in yeast genetics at the Telethon Institute for Child Health Research, Perth, Western Australia and the Department of Medicine at the University of Western Australia and Murdoch University. His research focused on the development of a novel class of peptides, trademarked by Phylogica as Phylomers® and the methods to integrate them into various high throughput screening platforms such as yeast- two-hybrid and phage display. Dr. Hopkins was elected to the position of Chair of Ausbiotech (WA Branch) in 2016. Dr. Hopkins served as an Executive Director of Phylogica Limited from July 19, 2013 to July 18, 2016. He has a BSc (Hons) and completed a PhD in Molecular Parasitiology.
Insufficient data for Richard to compare compensation growth.
Insufficient data for Richard to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Zelda Therapeutics management team is about average.
Co-Founder & Non-Executive Director
Co-Founder & Non-Executive Director
Co-Founder & Executive Director
MD & Director
Clinical Trial Consultant
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Zelda Therapeutics board of directors is less than 3 years, this suggests a new board.
Zelda Therapeutics Limited, a bio-pharmaceutical company, focuses on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoids to treat diabetes-associated cognitive decline. Zelda Therapeutics Limited has strategic partnership with CannPal Pty Ltd.; and St Vincent's Hospital on opioid reduction study. The company is based in Perth, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.